HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer

In a phase 2 trial, datopotamab deruxtecan plus durvalumab achieved a 50% overall pathologic complete response rate in patients with high-risk HER2-negative breast cancer.

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and treatment.

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in patients with early HER2-positive breast cancer treated with adjuvant chemotherapy and trastuzumab.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.